Atai Life Sciences N.V.
ATAI
$4.83
$0.091.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 510.85% | 572.56% | -1.91% | -0.90% | 39.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 510.85% | 572.56% | -1.91% | -0.90% | 39.48% |
| Cost of Revenue | -3.49% | -3.49% | -- | -- | -- |
| Gross Profit | 21.41% | 18.06% | -3,578.34% | -3,363.17% | -4,104.43% |
| SG&A Expenses | -19.39% | -26.04% | -26.40% | -6.92% | -10.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.10% | -13.87% | -18.29% | -17.54% | -21.32% |
| Operating Income | 10.91% | 15.29% | 18.33% | 17.58% | 21.44% |
| Income Before Tax | -91.22% | -288.05% | -234.29% | -105.15% | 56.34% |
| Income Tax Expenses | 70.09% | 37.33% | -2.66% | -141.97% | -136.23% |
| Earnings from Continuing Operations | -97.48% | -303.94% | -241.83% | -82.35% | 59.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -95.54% | -95.22% | -78.75% | -64.18% | -54.72% |
| Net Income | -105.61% | -340.75% | -271.09% | -92.11% | 59.97% |
| EBIT | 10.91% | 15.29% | 18.33% | 17.58% | 21.44% |
| EBITDA | 11.33% | 15.57% | 18.50% | 17.68% | 21.55% |
| EPS Basic | -95.49% | -332.02% | -263.87% | -89.51% | 61.44% |
| Normalized Basic EPS | 24.65% | -15.43% | -21.46% | -17.10% | -9.00% |
| EPS Diluted | -78.15% | -271.11% | -220.43% | -74.13% | 58.03% |
| Normalized Diluted EPS | 23.00% | -18.45% | -24.72% | -20.06% | -6.67% |
| Average Basic Shares Outstanding | 9.51% | 4.56% | 2.30% | 2.02% | 1.12% |
| Average Diluted Shares Outstanding | 5.87% | 1.06% | -1.14% | -1.41% | 4.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |